XML 96 R62.htm IDEA: XBRL DOCUMENT v3.25.1
SHARE-BASED PAYMENTS - Schedule of Share-based Compensation, Restricted Stock, Restricted Stock Units Activity and SAR's (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Payment Arrangement, Expense $ 2,832 $ 1,345
Share-Based Payment Arrangement, Amount Capitalized $ 230  
Equity Option    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) $ 3.35  
Nonvested, weighted average grant date fair value, end of period (in dollars per share) $ 2.46  
Employee Stock Option    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Payment Arrangement, Expense $ 818 448
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Unrecognized Compensation Costs Related To Unvested Stock Options 4,450  
Restricted Stock Units (RSUs)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Payment Arrangement, Expense $ 2,007 744
Restricted Stock Units (RSUs) | Equity Option    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]    
Number of nonvested shares, beginning of period (in shares) 1,143,146  
Granted, nonvested, number of shares (in shares) 1,429,418  
Vested, number of shares (in shares) (428,540)  
Forfeited, number of shares (in shares) (19,834)  
Number of nonvested shares, end of period (in shares) 2,124,190  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) $ 6.65  
Granted, nonvested, weighted average grant date fair value (in dollars per share) 5.56  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 5.59  
Vested, weighted average grant date fair value (in dollars per share) 7.05  
Nonvested, weighted average grant date fair value, end of period (in dollars per share) $ 5.84  
Stock Appreciation Rights (SARs)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Payment Arrangement, Expense $ 7 $ 153
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]    
Number of nonvested shares, beginning of period (in shares) 1,016,745  
Granted, nonvested, number of shares (in shares) 0  
Exercised, number of shares (in shares) 0  
Forfeited, number of shares (in shares) 0  
Expired (in shares) 0  
Number of nonvested shares, end of period (in shares) 1,016,745  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) $ 6.67  
Granted, nonvested, weighted average grant date fair value (in dollars per share) 0  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Exercise Price 0  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 0  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighted Average Grant Date Fair 0  
Nonvested, weighted average grant date fair value, end of period (in dollars per share) $ 6.67  
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Number 0  
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Exercise Price $ 0  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 2 years 18 days  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding $ 0  
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Aggregate Intrinsic Value $ 0  
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Remaining Contractual Term 0 years  
Stock Appreciation Rights (SARs) | Equity Option    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]    
Number of nonvested shares, beginning of period (in shares) 1,016,745  
Granted, nonvested, number of shares (in shares) 0  
Vested, number of shares (in shares) 0  
Forfeited, number of shares (in shares) 0  
Expired (in shares) 0  
Number of nonvested shares, end of period (in shares) 1,016,745  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) $ 3.83  
Granted, nonvested, weighted average grant date fair value (in dollars per share) 0  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 0  
Vested, weighted average grant date fair value (in dollars per share) 0  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighted Average Grant Date Fair 0  
Nonvested, weighted average grant date fair value, end of period (in dollars per share) $ 3.83